Regulus Therapeutics Inc. (NASDAQ:RGLS) CEO Sells $145,265.40 in Stock

Regulus Therapeutics Inc. (NASDAQ:RGLS) CEO Joseph P. Hagan sold 115,290 shares of the business’s stock in a transaction dated Monday, January 13th. The stock was sold at an average price of $1.26, for a total value of $145,265.40. Following the sale, the chief executive officer now owns 222,572 shares of the company’s stock, valued at $280,440.72. The trade was a 34.12 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.

Regulus Therapeutics Price Performance

Shares of NASDAQ RGLS opened at $1.24 on Friday. Regulus Therapeutics Inc. has a 1-year low of $1.13 and a 1-year high of $3.79. The company has a market capitalization of $81.22 million, a price-to-earnings ratio of -1.16 and a beta of 1.60. The business has a 50-day moving average of $1.52 and a 200-day moving average of $1.58.

Regulus Therapeutics (NASDAQ:RGLS) last released its quarterly earnings results on Thursday, November 7th. The biopharmaceutical company reported ($0.21) EPS for the quarter, missing the consensus estimate of ($0.18) by ($0.03). Research analysts expect that Regulus Therapeutics Inc. will post -0.88 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. Creative Planning acquired a new stake in Regulus Therapeutics during the 3rd quarter valued at $26,000. SG Americas Securities LLC acquired a new position in Regulus Therapeutics in the 3rd quarter worth $33,000. Jane Street Group LLC purchased a new position in Regulus Therapeutics in the 3rd quarter valued at about $46,000. JPMorgan Chase & Co. boosted its position in Regulus Therapeutics by 193.4% in the 3rd quarter. JPMorgan Chase & Co. now owns 78,972 shares of the biopharmaceutical company’s stock valued at $124,000 after buying an additional 52,059 shares during the last quarter. Finally, Barclays PLC grew its stake in shares of Regulus Therapeutics by 285.2% during the third quarter. Barclays PLC now owns 84,477 shares of the biopharmaceutical company’s stock valued at $132,000 after acquiring an additional 62,549 shares in the last quarter. 92.38% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Separately, HC Wainwright reaffirmed a “buy” rating and set a $10.00 price target on shares of Regulus Therapeutics in a research report on Monday, November 11th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and five have assigned a buy rating to the stock. According to MarketBeat.com, Regulus Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $10.80.

Regulus Therapeutics Company Profile

Regulus Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease.